Oct 19, 2017

MongoDB prices IPO above range

Smith Collection/Gado/Getty Images

MongoDB, a New York-based open source database company, has raised $192 million in its IPO. The company will begin trading today on the Nasdaq under ticker symbol MBD.

Why it's a big deal: MongoDB will be another critical data point for traders trying to decide if "unicorn" SaaS companies can ever really ride their recurring revenue models to profitability — or at least how to separate the future successes from the undercorns. To date, the trend too often has been: Strong IPO pricing, first day pop and then a steady slide.

Plus: NYC tech could really use a win, following yesterday's Blue Apron layoffs.

IPO details: The company priced 8 million shares at $24, above its upwardly-revised $20-$22 range, for a fully-diluted market cap of around $1.39 billion. The company reports a $46 million net loss on $68 million in revenue for the first half of 2017, compared to a $45 million net loss on $45 million in revenue for the year-earlier period. Morgan Stanley served as lead underwriter.

VC history: MongoDB had raised $300 million in VC funding, most recently at a post-money valuation of around $1.7 billion, from firms like Sequoia Capital (16.9% pre-IPO stake), Flybridge Capital (11.6%), Union Square Ventures (9.7%), NEA (7.2%), Future Fund (6.2%), Fidelity, Altimeter Capital Management and T. Rowe Price.

Go deeper

Caitlin Owens

Coronavirus stress tests drug industry's dependence on China

A Hong Kong commuter wears a face mask. Photo: Miguel Candela/SOPA Images/LightRocket via Getty Images

It's unclear whether the rapid spread of the novel coronavirus will actually result in prescription drug shortages, but it has undoubtedly highlighted the potential vulnerabilities of having the supply chain for American drugs so dependent on China.

Driving the news: About 150 prescription drugs — including antibiotics, generics and some branded drugs without alternatives — are at risk of shortage if the coronavirus outbreak in China worsens, per two sources familiar with a list of at-risk drugs compiled by the Food and Drug Administration.

Go deeper23 mins ago - Health

Jim VandeHei

Bernie's path to the presidency

Sen. Bernie Sanders speaks yesterday during a rally at Houston University. Photo: Mark Felix/AFP via Getty Images

Lots of Democrats are in full panic that Bernie Sanders will win the nomination and get clobbered in the general election — and bring the party down, too. But the evidence, particularly the polling, doesn't back those doomsday warnings.

Why it matters: Virtually every national and swing state poll shows Sanders tied with or beating President Trump. And, unlike every rival, he has a huge base of fervent, unshakable supporters he can only grow.

Go deeper51 mins ago - Politics & Policy

Amy Harder

These swing voters don't like Trump’s environmental rollbacks

Illustration: Sarah Grillo/Axios

Swing voters in four battleground states decisively oppose President Trump’s sweeping rollbacks of environmental regulations — but it’s unlikely to sway their votes.

Why it matters: It’s voters living in states like these, including Florida and Pennsylvania, who fill pivotal roles electing America’s presidents, so we should listen.

Go deeper1 hour ago - Energy & Environment